Matthew Galbraith
Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Down Syndrome | 16 | 2026 | 522 | 2.340 |
Why?
| | Cyclin-Dependent Kinase 8 | 8 | 2025 | 50 | 1.750 |
Why?
| | Cyclin-Dependent Kinases | 8 | 2025 | 122 | 1.450 |
Why?
| | Interferons | 6 | 2025 | 185 | 1.330 |
Why?
| | Transcriptome | 8 | 2026 | 1036 | 1.190 |
Why?
| | Tumor Suppressor Protein p53 | 9 | 2023 | 532 | 1.140 |
Why?
| | Transcription, Genetic | 9 | 2021 | 1468 | 1.070 |
Why?
| | Transcriptional Activation | 9 | 2023 | 372 | 0.960 |
Why?
| | Mediator Complex | 3 | 2013 | 61 | 0.820 |
Why?
| | Proteome | 5 | 2026 | 515 | 0.750 |
Why?
| | Blood | 1 | 2022 | 106 | 0.690 |
Why?
| | Seroconversion | 1 | 2021 | 48 | 0.650 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2024 | 294 | 0.650 |
Why?
| | Neoplasms | 8 | 2023 | 2873 | 0.640 |
Why?
| | Protein Kinase Inhibitors | 3 | 2025 | 971 | 0.580 |
Why?
| | Genomics | 2 | 2021 | 831 | 0.560 |
Why?
| | Signal Transduction | 10 | 2025 | 5185 | 0.520 |
Why?
| | RNA Polymerase II | 7 | 2019 | 351 | 0.510 |
Why?
| | Antineoplastic Agents | 4 | 2023 | 2201 | 0.500 |
Why?
| | Cell Hypoxia | 2 | 2017 | 248 | 0.480 |
Why?
| | ets-Domain Protein Elk-1 | 2 | 2013 | 11 | 0.470 |
Why?
| | Mitogens | 2 | 2013 | 55 | 0.460 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2013 | 174 | 0.440 |
Why?
| | Serum Response Element | 2 | 2011 | 6 | 0.410 |
Why?
| | Transcription Elongation, Genetic | 1 | 2013 | 24 | 0.390 |
Why?
| | Promoter Regions, Genetic | 3 | 2016 | 1246 | 0.320 |
Why?
| | Humans | 52 | 2026 | 144667 | 0.310 |
Why?
| | Hypoxia | 4 | 2024 | 1193 | 0.310 |
Why?
| | Eosinophilic Esophagitis | 2 | 2024 | 331 | 0.290 |
Why?
| | Anemia, Sickle Cell | 2 | 2023 | 312 | 0.290 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2021 | 1437 | 0.260 |
Why?
| | Apoptosis | 7 | 2025 | 2397 | 0.250 |
Why?
| | Nuclear Proteins | 4 | 2023 | 741 | 0.250 |
Why?
| | Cell Line, Tumor | 7 | 2023 | 3523 | 0.250 |
Why?
| | Glutamine | 2 | 2023 | 108 | 0.240 |
Why?
| | Cell Proliferation | 6 | 2023 | 2489 | 0.240 |
Why?
| | Animals | 19 | 2026 | 37948 | 0.240 |
Why?
| | Tumor Suppressor Proteins | 2 | 2018 | 319 | 0.230 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2026 | 179 | 0.230 |
Why?
| | Human Development | 1 | 2025 | 20 | 0.230 |
Why?
| | Homeodomain Proteins | 2 | 2020 | 523 | 0.230 |
Why?
| | Metabolome | 3 | 2026 | 385 | 0.220 |
Why?
| | Drug Discovery | 1 | 2026 | 153 | 0.220 |
Why?
| | Pantoea | 1 | 2004 | 2 | 0.220 |
Why?
| | Glutamate-Ammonia Ligase | 1 | 2004 | 9 | 0.220 |
Why?
| | DNA-Binding Proteins | 4 | 2017 | 1484 | 0.220 |
Why?
| | Phenazines | 1 | 2004 | 17 | 0.220 |
Why?
| | Datasets as Topic | 2 | 2022 | 119 | 0.220 |
Why?
| | Imidazoles | 3 | 2023 | 246 | 0.220 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2025 | 161 | 0.210 |
Why?
| | Janus Kinase Inhibitors | 1 | 2024 | 28 | 0.210 |
Why?
| | Immunoglobulins | 1 | 2025 | 160 | 0.210 |
Why?
| | Erythropoiesis | 1 | 2024 | 57 | 0.210 |
Why?
| | High-Throughput Screening Assays | 1 | 2026 | 176 | 0.210 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2024 | 42 | 0.210 |
Why?
| | Hemoglobin SC Disease | 1 | 2023 | 14 | 0.200 |
Why?
| | Heme | 1 | 2024 | 89 | 0.200 |
Why?
| | HCT116 Cells | 3 | 2019 | 78 | 0.200 |
Why?
| | Blood-Brain Barrier | 1 | 2025 | 155 | 0.200 |
Why?
| | Piperazines | 3 | 2023 | 378 | 0.200 |
Why?
| | Oxidative Phosphorylation | 1 | 2024 | 209 | 0.190 |
Why?
| | Liposarcoma | 1 | 2023 | 31 | 0.190 |
Why?
| | Sickle Cell Trait | 1 | 2023 | 15 | 0.190 |
Why?
| | Piperidines | 1 | 2024 | 219 | 0.190 |
Why?
| | Cell Line | 4 | 2025 | 2821 | 0.190 |
Why?
| | Hematopoiesis | 2 | 2021 | 193 | 0.190 |
Why?
| | Protein Tyrosine Phosphatases | 2 | 2023 | 167 | 0.190 |
Why?
| | HeLa Cells | 3 | 2013 | 632 | 0.190 |
Why?
| | Fibroblasts | 2 | 2019 | 1019 | 0.180 |
Why?
| | Proteomics | 3 | 2025 | 1183 | 0.180 |
Why?
| | Transcription Factors | 3 | 2023 | 1726 | 0.170 |
Why?
| | Cerebellar Neoplasms | 1 | 2023 | 177 | 0.170 |
Why?
| | Enteritis | 1 | 2022 | 104 | 0.170 |
Why?
| | Medulloblastoma | 1 | 2023 | 215 | 0.170 |
Why?
| | Hypoalbuminemia | 1 | 2021 | 27 | 0.170 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2023 | 454 | 0.170 |
Why?
| | Pyrimidines | 1 | 2024 | 519 | 0.170 |
Why?
| | Cell Differentiation | 3 | 2024 | 2037 | 0.170 |
Why?
| | Erythrocyte Transfusion | 1 | 2023 | 226 | 0.160 |
Why?
| | Genes, Tumor Suppressor | 1 | 2021 | 85 | 0.160 |
Why?
| | Autoimmunity | 2 | 2024 | 930 | 0.160 |
Why?
| | Seroepidemiologic Studies | 1 | 2021 | 171 | 0.160 |
Why?
| | Glycolysis | 2 | 2024 | 341 | 0.160 |
Why?
| | Case-Control Studies | 3 | 2025 | 3603 | 0.160 |
Why?
| | Oncogenes | 1 | 2021 | 118 | 0.160 |
Why?
| | Erythrocytes | 2 | 2023 | 750 | 0.160 |
Why?
| | Databases, Genetic | 1 | 2021 | 247 | 0.160 |
Why?
| | RNA Helicases | 1 | 2020 | 30 | 0.150 |
Why?
| | Sex Characteristics | 1 | 2025 | 776 | 0.150 |
Why?
| | Mice | 11 | 2026 | 18261 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 4 | 2023 | 67 | 0.150 |
Why?
| | Alzheimer Disease | 1 | 2025 | 622 | 0.150 |
Why?
| | Biomarkers | 4 | 2025 | 4261 | 0.150 |
Why?
| | Heart Defects, Congenital | 2 | 2026 | 905 | 0.140 |
Why?
| | Interferon-alpha | 1 | 2019 | 194 | 0.140 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 319 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2019 | 66 | 0.140 |
Why?
| | Epithelial Cells | 1 | 2024 | 1106 | 0.140 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2017 | 26 | 0.130 |
Why?
| | Hexokinase | 1 | 2017 | 18 | 0.130 |
Why?
| | Glucose Transporter Type 3 | 1 | 2017 | 15 | 0.130 |
Why?
| | Complement Activation | 1 | 2021 | 409 | 0.130 |
Why?
| | Complement System Proteins | 1 | 2021 | 314 | 0.130 |
Why?
| | Deoxyglucose | 1 | 2017 | 49 | 0.130 |
Why?
| | Inpatients | 1 | 2022 | 547 | 0.130 |
Why?
| | Liver | 1 | 2026 | 1889 | 0.130 |
Why?
| | Protein Biosynthesis | 1 | 2020 | 455 | 0.130 |
Why?
| | Homeostasis | 1 | 2021 | 639 | 0.130 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2017 | 374 | 0.120 |
Why?
| | Lysine Acetyltransferase 5 | 1 | 2016 | 2 | 0.120 |
Why?
| | Osteosarcoma | 1 | 2017 | 76 | 0.120 |
Why?
| | Gene Editing | 1 | 2017 | 91 | 0.120 |
Why?
| | Neurons | 1 | 2025 | 1639 | 0.120 |
Why?
| | Purines | 1 | 2017 | 187 | 0.120 |
Why?
| | Acetylation | 2 | 2016 | 249 | 0.120 |
Why?
| | Enhancer Elements, Genetic | 1 | 2017 | 192 | 0.120 |
Why?
| | Interferon-gamma | 1 | 2019 | 781 | 0.120 |
Why?
| | RNA-Binding Proteins | 1 | 2020 | 461 | 0.120 |
Why?
| | Comorbidity | 1 | 2021 | 1652 | 0.120 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2019 | 217 | 0.120 |
Why?
| | Conserved Sequence | 1 | 2016 | 247 | 0.110 |
Why?
| | Histone Acetyltransferases | 1 | 2016 | 57 | 0.110 |
Why?
| | NIH 3T3 Cells | 2 | 2013 | 147 | 0.110 |
Why?
| | Female | 16 | 2026 | 78304 | 0.110 |
Why?
| | Down-Regulation | 1 | 2017 | 616 | 0.110 |
Why?
| | Tretinoin | 1 | 2016 | 124 | 0.110 |
Why?
| | Nerve Tissue Proteins | 1 | 2019 | 590 | 0.110 |
Why?
| | Aging | 1 | 2025 | 1938 | 0.110 |
Why?
| | Phenotype | 4 | 2026 | 3147 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 407 | 0.110 |
Why?
| | HEK293 Cells | 2 | 2016 | 743 | 0.110 |
Why?
| | Bone Neoplasms | 1 | 2017 | 255 | 0.110 |
Why?
| | DNA Helicases | 1 | 2016 | 141 | 0.110 |
Why?
| | Drosophila Proteins | 1 | 2016 | 213 | 0.100 |
Why?
| | Drosophila melanogaster | 1 | 2016 | 237 | 0.100 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1319 | 0.100 |
Why?
| | Genes, Immediate-Early | 1 | 2013 | 26 | 0.100 |
Why?
| | Phosphorylation | 2 | 2019 | 1704 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2004 | 1928 | 0.100 |
Why?
| | Hemoglobin, Sickle | 2 | 2023 | 19 | 0.100 |
Why?
| | Bile Acids and Salts | 2 | 2026 | 163 | 0.100 |
Why?
| | Genes, ras | 1 | 2013 | 96 | 0.100 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2018 | 643 | 0.100 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2013 | 69 | 0.100 |
Why?
| | Models, Biological | 1 | 2021 | 1811 | 0.100 |
Why?
| | Protein Binding | 4 | 2021 | 2243 | 0.100 |
Why?
| | Child, Preschool | 5 | 2025 | 11790 | 0.090 |
Why?
| | Child | 7 | 2025 | 22600 | 0.090 |
Why?
| | Adult | 9 | 2025 | 40489 | 0.090 |
Why?
| | Gene Expression Regulation | 3 | 2025 | 2591 | 0.090 |
Why?
| | BH3 Interacting Domain Death Agonist Protein | 1 | 2012 | 11 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1145 | 0.090 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2012 | 31 | 0.090 |
Why?
| | bcl-2-Associated X Protein | 1 | 2012 | 52 | 0.090 |
Why?
| | Histones | 2 | 2016 | 663 | 0.090 |
Why?
| | Male | 11 | 2026 | 72431 | 0.090 |
Why?
| | Adolescent | 6 | 2025 | 22409 | 0.080 |
Why?
| | Young Adult | 5 | 2025 | 14122 | 0.080 |
Why?
| | Gene Silencing | 2 | 2023 | 202 | 0.080 |
Why?
| | Proto-Oncogene Proteins | 3 | 2023 | 619 | 0.080 |
Why?
| | Hospitalization | 1 | 2021 | 2446 | 0.080 |
Why?
| | Yeasts | 1 | 2010 | 51 | 0.080 |
Why?
| | Immunity, Innate | 1 | 2016 | 843 | 0.080 |
Why?
| | Disease Models, Animal | 3 | 2026 | 4539 | 0.080 |
Why?
| | Gene Expression Profiling | 3 | 2024 | 1766 | 0.080 |
Why?
| | MCF-7 Cells | 2 | 2020 | 132 | 0.070 |
Why?
| | Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2008 | 12 | 0.070 |
Why?
| | Middle Aged | 6 | 2025 | 35971 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2020 | 2365 | 0.060 |
Why?
| | Cytokines | 2 | 2024 | 2045 | 0.060 |
Why?
| | Neoplasm Metastasis | 2 | 2020 | 691 | 0.060 |
Why?
| | Cell Cycle Proteins | 2 | 2023 | 628 | 0.060 |
Why?
| | Tumor Cells, Cultured | 2 | 2019 | 881 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2020 | 925 | 0.060 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 68 | 0.060 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 125 | 0.060 |
Why?
| | Neurofilament Proteins | 1 | 2025 | 79 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2018 | 2660 | 0.050 |
Why?
| | Genetic Complementation Test | 1 | 2004 | 72 | 0.050 |
Why?
| | Mutagenesis, Insertional | 1 | 2004 | 68 | 0.050 |
Why?
| | Genes, Bacterial | 1 | 2004 | 170 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2023 | 3109 | 0.050 |
Why?
| | Cell Death | 1 | 2025 | 382 | 0.050 |
Why?
| | Hydroxyurea | 1 | 2023 | 34 | 0.050 |
Why?
| | Glutamates | 1 | 2023 | 66 | 0.050 |
Why?
| | Activating Transcription Factor 4 | 1 | 2023 | 22 | 0.050 |
Why?
| | Pyrroles | 1 | 2024 | 213 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2023 | 38 | 0.050 |
Why?
| | Erythropoietin | 1 | 2024 | 100 | 0.050 |
Why?
| | Pyruvates | 1 | 2023 | 24 | 0.050 |
Why?
| | Proline | 1 | 2023 | 82 | 0.050 |
Why?
| | Kynurenine | 1 | 2023 | 103 | 0.050 |
Why?
| | DNA, Bacterial | 1 | 2004 | 347 | 0.050 |
Why?
| | Tyrosine | 1 | 2023 | 219 | 0.050 |
Why?
| | Receptors, Interferon | 1 | 2023 | 60 | 0.050 |
Why?
| | Sphingosine | 1 | 2023 | 45 | 0.050 |
Why?
| | Cyclins | 1 | 2022 | 79 | 0.050 |
Why?
| | Lysophospholipids | 1 | 2023 | 78 | 0.050 |
Why?
| | Growth Disorders | 1 | 2022 | 86 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2023 | 153 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2021 | 2815 | 0.050 |
Why?
| | Mutation | 1 | 2013 | 4081 | 0.050 |
Why?
| | Esophagus | 1 | 2024 | 262 | 0.050 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2022 | 73 | 0.040 |
Why?
| | Hemolysis | 1 | 2023 | 242 | 0.040 |
Why?
| | Gastritis | 1 | 2022 | 116 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2004 | 828 | 0.040 |
Why?
| | Access to Information | 1 | 2021 | 47 | 0.040 |
Why?
| | Stress, Physiological | 1 | 2024 | 451 | 0.040 |
Why?
| | Infant | 2 | 2025 | 10023 | 0.040 |
Why?
| | Clonal Evolution | 1 | 2021 | 47 | 0.040 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 317 | 0.040 |
Why?
| | Data Mining | 1 | 2021 | 115 | 0.040 |
Why?
| | Polyribosomes | 1 | 2020 | 22 | 0.040 |
Why?
| | Eosinophilia | 1 | 2022 | 222 | 0.040 |
Why?
| | Nucleotide Motifs | 1 | 2020 | 36 | 0.040 |
Why?
| | Autoantigens | 1 | 2023 | 425 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2004 | 2909 | 0.040 |
Why?
| | Escherichia coli | 1 | 2004 | 854 | 0.040 |
Why?
| | BRCA1 Protein | 1 | 2020 | 82 | 0.040 |
Why?
| | Vesiculovirus | 1 | 2019 | 17 | 0.040 |
Why?
| | Cell Cycle Checkpoints | 1 | 2020 | 98 | 0.040 |
Why?
| | STAT1 Transcription Factor | 1 | 2019 | 66 | 0.040 |
Why?
| | 3' Untranslated Regions | 1 | 2020 | 150 | 0.040 |
Why?
| | Nanog Homeobox Protein | 1 | 2019 | 12 | 0.040 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2018 | 26 | 0.030 |
Why?
| | Genome, Human | 1 | 2021 | 420 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2020 | 211 | 0.030 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2018 | 76 | 0.030 |
Why?
| | Biomedical Research | 1 | 2025 | 712 | 0.030 |
Why?
| | Mice, SCID | 1 | 2019 | 368 | 0.030 |
Why?
| | Up-Regulation | 1 | 2021 | 848 | 0.030 |
Why?
| | Cell Survival | 1 | 2021 | 1092 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 967 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2021 | 452 | 0.030 |
Why?
| | Autoantibodies | 1 | 2024 | 1505 | 0.030 |
Why?
| | Rats | 1 | 2025 | 5570 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 610 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 441 | 0.030 |
Why?
| | Proteins | 1 | 2023 | 1016 | 0.030 |
Why?
| | Base Sequence | 1 | 2020 | 2177 | 0.030 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 2016 | 8 | 0.030 |
Why?
| | Promyelocytic Leukemia Protein | 1 | 2016 | 5 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 369 | 0.030 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2016 | 16 | 0.030 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2016 | 35 | 0.030 |
Why?
| | CCAAT-Enhancer-Binding Protein-beta | 1 | 2016 | 33 | 0.030 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2016 | 47 | 0.030 |
Why?
| | Mitosis | 1 | 2017 | 200 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1251 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 313 | 0.030 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2016 | 138 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1154 | 0.030 |
Why?
| | Metabolomics | 1 | 2021 | 724 | 0.030 |
Why?
| | Cohort Studies | 1 | 2026 | 5957 | 0.030 |
Why?
| | Protein Subunits | 1 | 2016 | 228 | 0.030 |
Why?
| | Cholesterol | 1 | 2017 | 404 | 0.030 |
Why?
| | Chromatin Assembly and Disassembly | 1 | 2016 | 108 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 339 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2017 | 428 | 0.030 |
Why?
| | RNA Interference | 1 | 2016 | 473 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2089 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2016 | 631 | 0.020 |
Why?
| | Monocytes | 1 | 2016 | 536 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2025 | 8284 | 0.020 |
Why?
| | Disease Progression | 1 | 2021 | 2847 | 0.020 |
Why?
| | Obesity | 1 | 2026 | 3070 | 0.020 |
Why?
| | Prospective Studies | 1 | 2025 | 7994 | 0.020 |
Why?
| | Quality of Life | 1 | 2025 | 3183 | 0.020 |
Why?
| | Caspase 8 | 1 | 2012 | 47 | 0.020 |
Why?
| | Chromatin | 1 | 2016 | 554 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2012 | 185 | 0.020 |
Why?
| | Binding Sites | 1 | 2014 | 1307 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2013 | 466 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2016 | 881 | 0.020 |
Why?
| | Protein Transport | 1 | 2012 | 437 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4312 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5414 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2016 | 4110 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 5967 | 0.020 |
Why?
| | Early Growth Response Protein 1 | 1 | 2008 | 32 | 0.020 |
Why?
| | Genes, fos | 1 | 2008 | 36 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2016 | 1984 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2008 | 220 | 0.020 |
Why?
| | RNA | 1 | 2014 | 926 | 0.020 |
Why?
| | Aged | 1 | 2025 | 25955 | 0.010 |
Why?
| | Mitochondria | 1 | 2012 | 984 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2008 | 592 | 0.010 |
Why?
|
|
Galbraith's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|